Board summary
Key figures
30,434
Registered population
52.5% aged 18–64
32.5%
Aged 65+
ICB 24.3% · England 17.9%
2.4%
Ethnic minority (non-White)
0.8% Asian · England 9.6%
6.0%
In IMD quintile 1
ICB 10.9% · England 21.0%
~1,713
Core20 residents (est.)
Resident basis; registered basis ~1,876 · see page 3
6,432
Hypertension register
+11.78% in 3 yrs · England +5.60%
246
SMI register
14.3% of Herefordshire, County of (LAD)'s
767
COPD register
Reviews -2.11% in 3 yrs
Forecast to 2030
8,238
Hypertension patients, 2030
+1,806 on today
70.1%
QRISK ≥20% on statins, 2030
+4.73pp over 3 yrs
8.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Diabetes and high-risk statin coverage trails England.
Diabetes statin treatment without CVD is 67.3% (England 73.2%, falling 4.5% vs England +2.1%) and QRISK ≥ 20% lipid therapy is 59.4% (England 63.6%).
COPD review coverage fell behind national growth.
COPD annual review coverage fell 2.1% to 72.0% (England +2.8%, 76.4%), alongside an estimated 695 asthma patients without a recorded 12-month review.
SMI physical health checks outpace national rates.
SMI BMI recording rose +16.4 pp to 91.3% (England +5.1 pp, 82.1%) and blood pressure checks reached 89.9% (England 83.4%).
Population, age and ethnicity
Adults aged 65+ comprise 32.5% of registrations, substantially above national benchmarks
Across 30,434 registered patients, 32.5% (9,901) are aged 65+, above Herefordshire (28.3%), the ICB (24.3%), and England (17.9%), which may increase frailty service need. Children aged 0–17 make up 14.9% (4,549), below Herefordshire (16.5%), the ICB (17.8%), and England (19.6%). Catchment Census data record 97.6% White residents against Herefordshire (96.9%), the ICB (94.6%), and England (81.1%), with a 2.4% non-White minority share. These Census figures reflect area residents rather than registered patients, while a 2.0% projected list growth to 2030 uses unverified methodology.
Age profile
65+: ICB 24.3%, England 17.9%
Ethnicity
Older people · falls rows are Herefordshire, County of (LAD) local-authority (LA) data, not PCN
| Measure | Local | West Midlands | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Herefordshire LA) | 1,472 | 1,847 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.3% | — | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.0% | — | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Herefordshire LA) | 772 | 922 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Herefordshire LA) | 10.4 | 17.5 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 6.0% network-wide and concentrates entirely at Nunwell Surgery
East Herefordshire PCN has a 6.0% Core20 share, below Herefordshire (7.8%), the ICB (10.9%) and England (21.0%). Average IMD decile is 5.7, compared to 5.5 in Herefordshire, 6.1 in the ICB and 5.5 in England. A reconciliation check shows the modelled weighted practice Core20 share of 6.2% differs from the 6.0% PCN rate by 0.13 percentage points. Deprivation is highly concentrated: Nunwell Surgery holds a 19.5% share (1,876 estimated patients), whereas Ledbury Health Partnership, Colwall Surgery and Cradley Surgery record 0.0%.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
246
SMI register
0.82% recorded prevalence
193
Learning disability register
0.64% recorded prevalence
22
Care homes, 576 beds
In the PCN catchment
8.7%
Provide unpaid care
Herefordshire, County of (LAD), Census 2021
The PCN records 246 patients on the severe mental illness register (0.8%; England 1.0%) and 193 on the learning disability register (0.6%; England 0.6%), alongside 22 catchment care homes with 576 beds. At borough level, the autumn 2025 rough sleeping snapshot recorded 16 people, while an 8.7% Census unpaid care rate provides an estimated ceiling of 2,648 unpaid carers.
Severe mental illness: physical health checks
Recorded SMI physical checks exceed comparators: 91.3% had BMI recorded (England 82.1%) and 89.9% had blood pressure checked (England 83.4%). Missing check elements cannot imply completed reviews. Comprehensive physical health checks require auditing uncaptured elements.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,432
Hypertension register
+11.78%
Register growth, 3 yrs
Herefordshire, County of (LAD) +10.36% · England +5.60%
−1.29pp
BP control, under 80
≤140/90 · −2.40pp aged 80+
+1,806
More patients by 2030
Forecast 8,238 (26.68%)
Hypertension case-finding and control
Hypertension prevalence is 21.4% (6,432 patients), above Herefordshire (19.2%), the ICB (18.7%) and England (15.2%), with a three-year change of +11.8% over 2023 to 2025 (England +5.6%). Although recent blood pressure recording reaches 92.5% (England 90.0%), treatment to target fell 1.8% over three years to 71.4% (England +3.6%), and control in patients aged 80+ is 79.2%, trailing England (81.2%) after falling 2.9% (England +2.2%). Age-unadjusted prevalence may reflect an older demography rather than confirmed case-finding. Trailing national benchmarks on blood pressure control in older cohorts suggests clinical review and medication titration could help improve control.
Lipids and statins
Statin coverage in diabetes without CVD is 67.3%, below Herefordshire (72.0%), the ICB (70.8%) and England (73.2%), falling 4.5% over three years (England +2.1%). QRISK ≥ 20% treatment is 59.4% (England 63.6%). Lower coverage than England across diabetic and high-risk cohorts suggests an opportunity to audit lipid therapy uptake.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 76,781 | £2.60 | £2.17 | £1.86 | £199,631 |
| Cardiovascular (all), 2025 | 100,610 | £4.02 | £4.41 | £3.33 | £404,452 |
In 2026, the PCN prescribed 76,781 lipid-modifying items at £2.60 per item, above Herefordshire (£2.44), the ICB (£2.17) and England (£1.86), spending £56,818 more than at England's unit cost. This indicator reflects unit cost differences rather than efficiency; local prescribing audits would test if formulary choices explain the variation.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+7.76%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.06%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.5% (767 patients; England 1.9%, ICB 2.2%), but 12-month COPD reviews fell 2.1% over three years to 72.0% (England +2.8% to 76.4%, ICB 76.8%). Smoking cessation support offered is 88.7% (England 94.2%). Recorded asthma prevalence is 7.9% (2,275 patients; England 6.6%), with 69.5% reviewed (England 65.7%), leaving about 700 patients unreviewed. Furthermore, asthma prescribing for ages 5-19 is 1,843 items per 1,000 (England 1,488). Slipping COPD reviews and high youth prescribing suggest proactive respiratory recall and inhaler reviews could be prioritized.
Cancer register and children's immunisation
Cancer: QOF prevalence (all ages) is 6.1% at PCN level, above Herefordshire, County of (LAD) (5.3%), above NHS Herefordshire and Worcestershire Integrated Care Board (5.1%) and above England (3.8%). This is above the comparator, which may reflect demography or recording; crude prevalence does not establish unmet need.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
56.2%
Herefordshire and Worcestershire ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~770
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Herefordshire and Worcestershire ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 52.4% | 53.2% | 23% | 706 |
| Bowel | 51.4% | 47.0% | 15% | 657 |
| Breast | 88.9% | 85.4% | 28% | 611 |
| Lung | 32.1% | 33.8% | 13% | 473 |
| Skin cancer | 86.3% | 87.8% | 13% | 314 |
In 2022, 56.2% of staged cancers across NHS Herefordshire and Worcestershire ICB were diagnosed at stage 1 or 2, 0.9 percentage points above England (55.3%) but 18.8 pp below the 75.0% national ambition. Known stage was recorded for 68.0% of cancers (4,068 of 5,984), and early-stage share fell 2.7 pp between 2013 and 2022. Closing the gap to the 75% ambition required 766 extra early diagnoses across the ICB. These figures reflect system performance, not the PCN. Locally, cervical screening in women aged 25 to 49 is 68.8%, trailing the ICB benchmark of 70.9%, with Ledbury Health Partnership at 64.9% and Nunwell Surgery at 68.3%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data, Wye Valley NHS Trust met the 85.0% 62-day cancer standard at 85.1%, ahead of Gloucestershire Hospitals NHS Foundation Trust (74.6%), Worcestershire Acute Hospitals NHS Trust (53.0%), the ICB (61.7%) and England (71.2%). Its 28-day faster diagnosis reached 86.5% (ICB 83.0%; England 79.3%) and 31-day treatment reached 96.2% (standard 96.0%). For Wye Valley NHS Trust, 6+ week diagnostic waits reached 40.0% for colonoscopy (England 30.8%) and 48.7% for flexi sigmoidoscopy (England 32.1%). Trust metrics describe wider provider activity rather than PCN-specific performance.
| Pathways within standard (%) | Wye Valley | Worcestershire Acute | Gloucestershire | Herefordshire and Worcestershire ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 86.52 | 82.50 | 74.43 | 83.05 | 79.32 |
| 31-day treatment (96%) | 96.25 | 86.98 | 94.66 | 89.95 | 92.50 |
| 62-day referral to treatment (85%) | 85.14 | 52.99 | 74.59 | 61.71 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wye Valley | Worcestershire Acute | Gloucestershire | England |
|---|---|---|---|---|
| MRI | 18.23 | 22.51 | 15.96 | 21.40 |
| CT | 0.16 | 11.09 | 7.44 | 9.92 |
| Echocardiography | 30.24 | 10.25 | 56.17 | 28.48 |
| Colonoscopy | 40.00 | 9.91 | 40.00 | 30.83 |
| Gastroscopy | 26.09 | 9.53 | 31.55 | 29.02 |
| All 15 DM01 tests | 19.35 | 30.61 | 18.34 | 23.14 |
| Community services activity | Herefordshire, County of residents | Herefordshire and Worcestershire ICB |
|---|---|---|
| Care contacts | 43,135 | 124,085 |
| Referrals | 5,970 | 23,130 |
| Patients with a contact | 9,550 | 30,665 |
Community services (residents of Herefordshire, County of), Jun 2026 (provisional). In provisional June 2026 community services data, contacts with adults aged 65 and over accounted for 67.4% of all community contacts among Herefordshire residents (29,080 of 43,135). These figures capture activity across local authority residents rather than registered PCN patients.
Practice variation and patient experience
Patient phone access spans 49.6 percentage points across member practices
In 2025/26, clinical QOF achievement was 99.9% at Colwall Surgery and 100.0% at the other three practices (England 97.1%). Overall points exceeded England (92.5%), reaching 93.5% to 97.4%. Vaccination achievement spanned 34.0 pp, from 43.1% at Ledbury Health Partnership to 77.1% at Cradley Surgery (England 55.2%). High clinical scores mask wide variation in immunisation coverage.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Cradley Surgery | 120 | 0.0 | 93.0% | 70.3% | 95.4% |
| Nunwell Surgery | 109 | 19.5 | 87.6% | 77.8% | 93.1% |
| Colwall Surgery | 130 | 0.0 | 84.0% | 69.2% | 80.7% |
| Ledbury Health | 111 | 0.0 | 43.4% | 81.6% | 62.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven measures trail England's three-year change, while mental health checks outpaced national trends
Across 25 clinical indicators over 2023 to 2025, 11 measures lagged England's three-year trajectory. The widest shortfalls in relative change occurred in diabetes statin prescribing without cardiovascular disease, which fell 4.5% (England +2.1%), hypertension treatment to target, falling 1.8% (England +3.6%), and COPD reviews, down 2.1% (England +2.8%). In contrast, severe mental illness physical checks outpaced national progress in percentage-point gains: BMI recording rose 16.4 pp to 91.3% (England +5.1 pp) and blood pressure checks rose 10.4 pp to 89.9% (England +4.4 pp), alongside a 17.9% increase in recorded dementia prevalence (England +6.0%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Diabetes statin (no CVD)
Hypertension treated to target
BP control, 80+
BP control, under 80
COPD reviews
BMI record (SMI)
Alcohol record (psychosis)
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Herefordshire, County of (LAD) | Asset | PCN | Herefordshire, County of (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 22 (576 beds) | n/a | Schools (catchment) | 47 | n/a |
| Children's centres | 2 | 7 | Places of worship | 83 | 341 |
| Libraries | 2 | 9 | Day centres (VCS) | 1 | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 6 | 43 |
| Primary academies | 10 | 28 | Special schools | 3 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory recall and inhaler reviews
COPD reviews fell 2.1% over 2023 to 2025 to 72.0% (England +2.8%, 76.4%), smoking cessation support is 88.7% (England 94.2%), and 69.5% asthma review coverage across 2,275 patients leaves 695 (about 700) unreviewed. Moderate effort to run.
Evidence base: delivery measure for spirometry-confirmed diagnosis; shortfall here is what shows up later as emergency admission.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 2
Pharmacist-led lipid therapy and formulary review
Statin therapy in diabetes (40+ without CVD) fell 4.5% over 2023 to 2025 to 67.3% (England +2.1%, 73.2%), with CVD is 76.5% (England 84.4%), and QRISK >= 20% lipid therapy is 59.4% (England 63.6%). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Hypertension titration audit for older adults
Across 6,432 hypertension patients (21.4%; England 15.2%), treatment to target fell 1.8% over 2023 to 2025 to 71.4% (England +3.6%), and control in patients aged 80+ fell 2.9% to 79.2% (England +2.2%, 81.2%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult proactive care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 health outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Sustain SMI physical health checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Targeted cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured respiratory recall and inhaler reviews (p12) | COPD patients with a review in the last 12 months · Patients with COPD who had a review in the last 12 months (denominator incl. PCAs) · Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pharmacist-led lipid therapy and formulary review (p12) | Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
| Option 3 · Hypertension titration audit for older adults (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
